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Background: We have demonstrated that anorexia nervosa is underpinned by overwhelming 
adrenal sympathetic activity which abolishes the neural sympathetic branch of the peripheral 
autonomic nervous system. This physiological disorder is responsible for gastrointestinal hypo-
motility, hyperglycemia, raised systolic blood pressure, raised heart rate, and other neuroendo-
crine disorders. Therefore, we prescribed neuropharmacological therapy to reverse this central 
and autonomic nervous system disorder, in order to normalize the clinical and neuroendocrine 
profile.
Methods: The study included 22 female patients with anorexia nervosa (10 restricted type, 12 
binge-eating type) who received three months of treatment with amantadine 100 mg/day. We 
measured blood pressure, heart rate, and circulating neurotransmitters, (noradrenaline,   adrenaline, 
dopamine, platelet serotonin, free plasma serotonin) during supine resting, one minute of orthos-
tasis, and a five-minute exercise test before and after one, two, and three months of treatment 
with amantadine, a drug which abrogates adrenal sympathetic activity by acting at the C1(Ad) 
medullary nuclei responsible for this branch of the peripheral sympathetic activity.
Results: We found the amantadine abolished symptoms of anorexia nervosa from the first 
oral dose onwards. Normalization of autonomic and cardiovascular parameters was dem-
onstrated within the early days of therapy. Abrupt and sustained increases in the plasma 
noradrenaline:adrenaline ratio and disappearance of abnormal plasma glucose elevation were 
registered throughout the three-month duration of the trial. Significant and sustained increases 
in body weight were documented in all cases. No relapses were observed.
Conclusion: We have confirmed our previously published findings showing that the anorexia 
nervosa syndrome depends on the hypomotility of the gastrointestinal tract plus hyperglyce-
mia, both of which are triggered by adrenal sympathetic hyperactivity. The above neuroendo-
crine plus neuroautonomic and clinical disorders which underpinned anorexia nervosa were 
abruptly suppressed since the first oral dose of amantadine, a drug able to revert the C1(Ad) 
over A5(NA) pontomedullary predominance responsible for adrenal and neural sympathetic 
activity, respectively. 
Keywords: amantadine, anorexia nervosa, adrenal sympathetic activity, hyperglycemia, 
  hyperinsulinism, neural sympathetic activity
Introduction
We have demonstrated that doxepin, a drug which inhibits the uptake of serotonin 
(5-HT) is able to normalize patients affected by the hyperinsulinism plus hypoglycemia 
syndrome.1 We have also shown that amantadine, a N-methyl-D-aspartate (glutamate) 
antagonist, is able to enhance insulin secretion and lower plasma glucagon levels.2–8 
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attenuation of neural sympathetic and adrenal sympathetic 
activity, respectively, we inferred that neuropharmacologi-
cal drugs able to attenuate the hyperactivity of the C1(Ad) 
  medullary nuclei3–8 might be powerful tools for treating 
adrenal sympathetic predominance, including the anorexia 
nervosa syndrome.
In view of these observations, along with our previous 
demonstration that the anorexia nervosa syndrome (both 
restricted type and binge-eating type) is underpinned by max-
imal adrenal sympathetic overactivity,9 we tested the potential 
therapeutic effects of amantadine, a   N-methyl-D-aspartate 
antagonist that interferes with excitatory glutamate axons 
at the medullary C1(Ad) nuclei in patients affected by this 
pathophysiological disorder.
Methods
The study was conducted in accordance with the guidelines 
of the Declaration of Helsinki. Written informed consent was 
obtained after the purpose, nature, and potential risks had 
been explained to the subjects. The experimental protocol 
was approved by the ethical committee of the Fundación 
Instituto Medicina Experimental.
Patients
The study included 22 female patients with anorexia 
  nervosa (10 restricted type and 12 binge-eating type) before 
treatment9 and after three months of treatment with aman-
tadine 100 mg/day. The diagnoses were made according 
to Diagnostic and Statistical Manual of Mental Disorders 
Fourth Edition criteria. The mean age ± standard deviation 
of the patients was 22  ± 6.4 years and body weight was 
70 ± 10.1% of ideal weight, according to Metropolitan Life 
Insurance Company tables. All patients had been exten-
sively evaluated (physically, endoscopically, radiologically, 
biochemically, bacteriologically, and immunologically) 
to rule out any other physical illness, as explained in our 
previously published study.9 Exclusion criteria included 
pregnancy, lactation, smoking, and alcohol abuse. The 
patients did not take any medication for 15 days prior to 
the beginning of the study.
Measurement of blood pressure and heart rate, as well as 
drawing of blood samples, were performed   simultaneously. 
Supine blood pressure measurements were taken in a 
  standardized fashion using appropriate-sized cuffs and a 
  random-zero mercury sphygmomanometer. All   measurements 
were taken in accordance with a previously published   protocol.10 
Blood samples for plasma neurotransmitter determination were 
obtained simultaneously with blood pressure and heart rate 
measurements through a heparinized catheter inserted into the 
contralateral antebrachial vein 15 minutes before the first blood 
pressure and heart rate measurements. Plasma noradrenaline, 
adrenaline, dopamine, free serotonin (f5-HT), and platelet 
serotonin (p5-HT) levels were assessed during supine resting, 
one minute of orthostasis, and after five minutes of moderate 
exercise. All tests were performed on the subjects after 10 hours 
of fasting. A physician was in constant attendance, and noted 
any symptoms reported by the subjects.
Analytic methods
Noradrenaline, adrenaline, dopamine, plasma f5-HT, and 
p5-HT levels were measured. For all parameters, the samples 
were assayed in duplicate, and all determinations were made 
simultaneously. We used reverse-phase, ion-pair high-
performance liquid chromatography with electrochemical 
detection for the measurement of monoamines. Optimization 
of chromatographic conditions and attainment of adequate 
quantification parameters allowed us to maximize sensitivity 
and reproducibility.
Blood for catecholamine and serotonin assays was 
transferred to plastic tubes, each containing 20 mg of 
  ethylenediamine tetra-acetic acid and 10 mg of sodium 
bisulfite/mL in solution. The tubes were carefully inverted 
and placed on ice. The blood was promptly centrifuged at 
600 rpm for 15 minutes at 4°C in order to obtain platelet-rich 
plasma. Two milliliters of platelet-rich plasma, obtained for 
determination of p5-HT, were taken and stored at -70°C 
until assayed. The remaining blood was again centrifuged at 
7000 rpm. The supernatant platelet-poor plasma was divided 
into two portions for determination of catecholamines and 
f5-HT, after which the portions were stored at -70°C until 
assayed.
Reagents and standards
Noradrenaline, adrenaline, dopamine, serotonin   creatinine 
sulfate, dihydroxybenzylamine, sodium octyl sulfate, 
  dibutylamine, acid-washed aluminum oxide, KH2PO4, citric 
acid, and ethylenediamine tetra-acetic acid were purchased 
from Sigma-Aldrich (St Louis, MO). Microfilters were 
purchased from Whatman Inc (Florham Park, NY) through 
Merck SA, (Caracas, Venezuela). Acetonitrile and   2-propanol 
were obtained from Merck SA. Glass-distilled water was 
deionized and filtered through a Millipore Milli-Q reagent 
grade water system (Bedford, MA). Solvents were filtered 
through a 0.2 µm Millipore filter and were vacuum deaerated. 
Standard solutions (1 mmo1/L) were prepared in 0.1 mo1/L 
perchloric acid and diluted to the desired concentration.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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equipment
Liquid chromatography was performed using a Waters 515 
HPLC pump (Waters Corporation, Milford, MA) equipped with 
a Rheodyne valve injector 7125i, which was fitted with a 50 µL 
sample loop (Rheodyne, Berkeley, CA). A 15 cm × 4.6 mm 
inner diameter Discovery C18 column packed with   octadecyl 
silane 5 µm particles was preceded by a column prefilter of 2 µm 
porosity, both from Supelco/Sigma-Aldrich. The detection sys-
tem was a 460   electrochemical detector (Waters   Corporation). 
The potential of the glass   carbon working electrode was set 
at ±0.61 V versus the   Ag-AgCl reference electrode for detec-
tion of catecholamines and 0.70 V versus the   Ag-AgCl for 
detection of indolamines. The chromatograms were registered 
and quantified using Empower software (Waters Corporation). 
The results were corrected for the volume of ethylenediamine 
tetra-acetic acid added.
Analytical assays
Plasma catecholamines
The assay was performed by extraction of the catecholamines 
onto 20 mg of alumina followed by elution with 200 µL 
of 1.0 mo1/L HClO4 using regenerated cellulose micro-
filters of 0.2 µm pore size purchased from Whatman Inc 
  (Piscataway, NJ). We calibrated the instrument with standard 
plasma. After incubation with acid-washed aluminum oxide, a 
plasma pool of free catecholamines was processed similarly to 
the plasma samples, but 20 µL of a standard solution of nora-
drenaline, adrenaline, and dopamine (50, 25, and 25 ng/mL, 
respectively) was added to the plasma pool. Both the standard 
plasma and the sample plasma were supplemented with 20 µL 
of internal standard (dihydroxybenzylamine 100 ng/mL). The 
mobile phase was KH2PO4 6.8045 g/L, ethylenediamine tetra-
acetic acid 0.1 g/L, and di-N-butylamine 100 µL/L. Sodium 
octyl sulfate was added as an ion-pair agent at a concentration 
of 0.6125 g/L, with the pH adjusted to 5.6. The flow rate was 
0.4 mL/min. The sensitivities of this method for noradrena-
line, adrenaline, and dopamine, were 6.4, 5.8, and 2.0 pg/mL, 
respectively. The intra-assay coefficients of variation were 
2.8, 4.0, and 4.0%, respectively. The interassay coefficients 
of variation were 6.7, 4.5, and 4.3%, respectively.
Plasma indolamines
After sonication of platelet-rich plasma to disrupt the   platelets 
(Ultrasonic Liquid Processor, Model 385; Heat Systems 
Ultrasonics Inc, Farmingdale, NY), both platelet-rich and 
platelet-poor plasma samples were processed in the same 
way, ie, 200 µL of 3.4 mol/L perchloric acid and 50 µL 
of 5-hydroxytryptophan solution (114.5 µg/mL) as the 
internal standard, were added to 1 mL of plasma   vortexed 
and   centrifuged at 10,000 rpm for 15 minutes at 4°C. The 
  supernatant was filtered through a 0.22 µm membrane 
(Millipore) and 10 µL was injected into the column. 
  Calibration runs were   generated by spiking blank platelet-
poor plasma with 50 µL of a solution containing 5-HT 
10 µg/mL) and 50 µL of 5-HT 114.5 µg/mL. This standard 
plasma was processed in the same manner as the samples. 
The mobile phase was citric acid 3.8424 g/L, sodium acetate 
4.1015 g/L, ethylenediamine tetra-acetic acid 0.100 g/L, 
di-N-butylamine 100 µL/L, and 30 mL/L of 2-propanol. 
Sodium octyl sulfate was added as an ion-pair agent at a con-
centration of 4.25 mg/L, with a pH of 5.0. The flow rate was 
0.610 mL/min. The sensitivity of the method for serotonin 
was 0.1 ng/mL. The intra-assay coefficients of variation for 
p5-HT and f5-HT were 6.2 and 8.7%, respectively.
statistical methods
The results are presented as the mean ± standard error of 
measurement. Multivariate one-way analysis of variance 
with repeated measurements, and correlation coefficients 
(exploratory factor analysis) were used. Dbase Stats by 
Ashton Tate and Statview SE ± Graphics by Abacus were 
used for the statistical analysis.
Results
We have previously demonstrated that there are no significant 
neuroendocrine or neuroautonomic differences between the 
two clinical types of anorexia nervosa, ie, the restricted and 
binge-eating types.9
Cardiovascular parameters
Neither systolic nor diastolic blood pressure showed signifi-
cant variations during orthostasis or after moderate exercise 
in our patients. However, differential pressure showed a 
significant increase during orthostasis before but not after 
amantadine treatment. Heart rate showed significant and 
progressive rises during both orthostasis and exercise periods 
before but not after amantadine treatment (Table 1).
Catecholamines
Plasma noradrenaline showed significant and progressive 
increases during orthostasis and exercise in the two groups. 
However, the noradrenaline values and their increases were 
significantly higher after amantadine therapy. In addition, 
adrenaline showed important and significant increases dur-
ing orthostasis and exercise in the patients before treatment 
but not in treated patients. Plasma dopamine levels showed a Therapeutics and Clinical Risk Management 2011:7
Table 1 systolic, diastolic blood pressure, heart rate, noradrenaline, adrenaline, dopamine, platelet serotonin, and free blood serotonin 
blood values, at 0 minutes (resting), one minute (orthostasis), and five minutes (postexercise) in 22 patients with anorexia nervosa 
during a symptomatic period and during an asymptomatic period three months after treatment with amantadine 100 mg/day
0 min 1 min 5 min P values
0 vs 1 min 0 vs 5 min 1 vs 5 min
sBP Ans 152 ± 5 15 ± 3 17 ± 6 ,0.05* ,0.02* ,0.02*
Ana 120 ± 3 12 ± 4 13 ± 6 ns ns ns
DBP Ans 60 ± 3 60 ± 2 61 ± 3 ns ns ns
Ana 74 ± 4 70 ± 4 76 ± 6 ns ns ns
hR Ans 71 ± 3 79 ± 4 83 ± 6 ,0.02** ,0.01** ,0.01**
Ana 66 ± 6 64 ± 4 74 ± 6 ns ns ns
nA Ans 166 ± 4 169 ± 5 175 ± 5 ns ns ns
Ana 186 ± 6 214 ± 8 235 ± 7 ,0.05* ,0.01** ,0.01**
Ad Ans 52 ± 2 67 ± 3 84 ± 4 ,0.05* ,0.001*** ,0.001***
Ana 27 ± 5 30 ± 4 35 ± 3 ns ns ns
DA Ans 18 ± 1 21 ± 2 23 ± 2 ns ns ,0.05*
Ana 15 ± 4 20 ± 4 22 ± 5 ns ns ns
p5-hT Ans 228 ± 19 249 ± 22 225 ± 25 ns ns ns
Ana 258 ± 31 316 ± 27 308 ± 32 ns ns ns
f5-hT Ans 3.2 ± 1 13.7 ± 1 24.5 ± 2 ,0.001*** ,0.001*** ,0.001***
Ana 2.1 ± 1 2.3 ± 1 3.1 ± 1 ns ns ns
Notes: Values are mean ± standard error of the mean. *P , 0.05; **P , 0.02; ***P , 0.001. 
Abbreviations: Ana, asymptomatic of anorexia nervosa; Ans, symptomatic of anorexia nervosa; DBP, diastolic blood pressure (mmhg); sBP, systolic blood pressure 
(mmhg); hR, heart rate (beats/min); nA, noradrenaline (pg/mL); Ad, adrenaline (pg/mL); DA, dopamine (pg/mL); p5-hT, platelet serotonin (ng/mL); f5-hT, free serotonin 
(ng/mL); ns, not significant.
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significant increase during orthostasis in nontreated patients 
but not in treated patients.
indolamines
p5-HT did not show any significant variation before or after 
treatment. Plasma f5-HT, (ie, outside the platelets) showed 
mean basal values which were greater before treatment and 
showed progressive and significant decreases after   amantadine 
treatment. Significant correlations between the different physi-
ologic and neurochemical variables during rest, orthostasis, 
and after moderate exercise are shown in Table 2.
Discussion
Our results show that a low dose (100 mg/day) of amanta-
dine, a drug which abruptly suppresses adrenal sympathetic 
activity,9,11 was able to abolish symptoms of anorexia nervosa 
in 22 affected patients when it was administered 45 minutes 
before the main meal, and also when it was administered 
45 minutes before an oral glucose tolerance test (manuscript 
in preparation). Patients were able to eat all types of foods 
and recovered their normal body weight. Normalization of 
cardiovascular parameters (enhancement of diastolic blood 
pressure and reduction of systolic blood pressure and heart 
rate) were registered in all cases. Namely, the present research 
confirms that the anorexia nervosa syndrome is underpinned 
by an overwhelming predominance of adrenal sympathetic 
branch activity which abrogates neural   sympathetic   activity. 
This pathophysiological disorder includes symptoms at all 
levels (cardiovascular, digestive, metabolic, endocrine, respi-
ratory, etc), as well as psychological and neuroautonomic 
disturbances.
Understanding of the pathophysiology of anorexia ner-
vosa syndrome requires knowledge about hyperactivity of 
the adrenal sympathetic branch9,12,13 which is responsible for 
gastrointestinal hypoactivity,9,14–17 systolic blood pressure and 
heart rate enhancement, hyperglycemia, tracheobronchial 
dilation + hypersecretion, and anxiety.18 Neuroendocrine and 
metabolic disorders should also be included into this syndrome, 
the source of which is located at the medullary C1(Ad) nuclei 
responsible for the peripheral adrenal sympathetic branch.19,20 
The findings presented in this study demonstrate also that an 
oral dose of amantadine, a N-methyl-D-aspartate antagonist 
which annuls the firing activity of the C1(Ad) medullary 
nuclei,11 minimizes systolic blood pressure and heart rate, both 
of which are cardiovascular parameters positively correlated 
with adrenal sympathetic activity. The recovery of gastroin-
testinal motility and normal feeding were paralleled by a body 
weight increase. These clinical and physiological parameters Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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were paralleled by normalization of the insulin versus glucagon 
balance   throughout the oral glucose tolerance test.2
The dramatic therapeutic effect triggered by amantadine 
supports our hypothesis that the drug acts through central 
nervous system mechanisms. With respect to this, we now 
summarize some information dealing with this issue. The 
C1(Ad) medullary and the A5(NA) pontine nuclei are the 
motor centers of the adrenal and neural sympathetic branches 
of the peripheral autonomic system, respectively.3–8 Glutamate 
axons excite the former but not the latter nuclei. However, both 
nuclei interchange inhibitory axons which act at   postsynaptic 
alpha-2 inhibitory receptors.3–8 The C1(Ad) nuclei send 
polysynaptic drives to both pancreatic A cells (secreting 
glucagon) and to the adrenal glands (secreting adrenaline).21 
Conversely, A5(NA) neurons send polysynaptic drives to 
the lumbar sympathetic neurons which excite sympathetic 
  ganglia (whose axons release noradrenaline preferentially 
and dopamine). In addition, insulin released from B cells 
crosses the blood–brain barrier and excites the A5(NA) 
neurons,3–5,22–25 whereas glucagon secreted from A cells crosses 
the   blood–brain barrier and excites the C1(Ad) nuclei.26–30
Circulating insulin triggers hypoglycemia and enhances 
gastrointestinal motility and feeding, whereas glucagon pro-
vokes hyperglycemia and abrogates gastrointestinal motility, 
both of which are factors responsible for anorexia.1,9,19,23,31 
This central and autonomic neuroendocrine interaction 
facilitates the understanding of the dramatic annulment of 
anorexia nervosa syndrome provoked by a small oral dose of 
amantadine, a drug that interrupts the central nervous system 
C1(Ad) and A cell (glucagon) crosstalk.
Some additional information should facilitate the under-
standing of the above issue. We were able to demonstrate 
that insulin crosses the blood–brain barrier and excites the 
noradrenergic neurons responsible for peripheral neural 
sympathetic activity,22 and our findings have been confirmed 
by other authors.25 Furthermore, we have also demonstrated 
that postprandial hypoglycemia and hyperinsulinism are 
provoked by the predominance of this sympathetic branch. 
Furthermore, we found that neuropharmacological manipula-
tion to attenuate the neural sympathetic predominance was 
able to normalize this postprandial hypoglycemia and hyper-
insulinism disorder.1,23 These findings are now complemented 
by the results presented here, showing that the anorexia 
nervosa syndrome is located on the opposite “side of the 
coin”, namely, adrenergic hyperactivity and hyperglycemia, 
which may be abrogated by adequate neuropharmacological 
manipulation.
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Table  2  Significant  correlations  for  physiological  and  plasma  neurotransmitter  parameters  at  0  minutes  (resting),  one  minute 
(orthostasis), and five minutes (postexercise) in 22 patients with anorexia nervosa during a symptomatic pretreatment period and 
during an asymptomatic period three months after treatment with amantadine 100 mg/day
SBP DBP HR NA Ad DA p5-HT f5-HT
ANs 0 min
hR 0.61*
Ad 0.66* 0.70*
DA 0.64*
f5-hT 0.70* 0.70*
ANa 0 min
hR 0.63*
ANs 1 min
hR 0.60*
Ad 0.60* 0.69**
DA 0.63**
f5-hT 0.60* 0.69*
ANa 1 min
Ad 0.63*
ANs 5 min
hR 0.70**
Ad 0.75** 0.80***
f5-hT 0.66* 0.68*
Notes: *P , 0.05; **P , 0.02; ***P , 0.001. 
Abbreviations: Ana, asymptomatic of anorexia nervosa; Ans, symptomatic of anorexia nervosa; DBP, diastolic blood pressure (mmhg); sBP, systolic blood pressure (mmhg); 
hR, heart rate (beats/min); nA, noradrenaline (pg/mL); Ad, adrenaline (pg/mL); DA, dopamine (pg/mL); p5-hT, platelet serotonin (ng/mL); f5-hT, free serotonin (ng/mL).Therapeutics and Clinical Risk Management
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